SCHEDULE: Logos Global Management Adjusts Yarrow Bioscience Stake

Logos Global Management LP and affiliated entities have reported an amendment to their Schedule 13G filing, detailing changes in their beneficial ownership of Yarrow Bioscience, Inc. common stock.

Summary

• Logos Global Management LP and its affiliates have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Yarrow Bioscience, Inc. common stock.
• The filing indicates a combined beneficial ownership of 286,308 shares for Logos Global Management LP, Logos Global Management GP LLC, and Arsani William, representing 10.7% of the class.
• Logos Global Master Fund LP and Logos GP LLC collectively hold 176,678 shares (6.6%), while Logos Opportunities Fund V LP, Logos Opportunities V GP LLC, and Graham Walmsley hold 109,630 shares (4.1%).
• The reported shares exclude pre-funded warrants subject to a 9.99% beneficial ownership limitation.
• The percentage calculations are based on 2,669,788 shares of Common Stock outstanding as of July 29, 2026, as per the Issuer's Form 8-K filed on July 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports changes in beneficial ownership without disclosing new strategic information or financial performance.

Positives

• The filing clarifies the beneficial ownership structure of Yarrow Bioscience, Inc. by key investment entities and individuals.
• The reporting persons have disclaimed beneficial ownership beyond their pecuniary interest, adhering to regulatory transparency.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Yarrow Bioscience, Inc.

Risks

• The beneficial ownership is subject to a 9.99% limitation for pre-funded warrants, which could impact future ownership levels.
• The reporting persons have explicitly disclaimed membership in a group, which could have implications for coordinated actions.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Yarrow Bioscience, Inc.'s future performance.

Management Comments

• Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein.
• The filing of this Schedule 13G on behalf of each of the Global Fund or Opp Fund V should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors crossing certain ownership thresholds. This filing indicates significant, though not controlling, stakes held by Logos Global Management and its affiliates in Yarrow Bioscience, Inc., a biotechnology company.

Stakeholder Impact

• Shareholders: The filing provides transparency on significant ownership by institutional investors, which can influence market perception and potential future corporate actions.
• Management: The disclosure confirms the investment positions of Logos Global and its key personnel, impacting their relationship with Yarrow Bioscience's board and management.

Next Steps

• Logos Global Management and its affiliates will continue to monitor their beneficial ownership levels in Yarrow Bioscience, Inc.
• Further amendments to Schedule 13G will be filed if ownership thresholds change.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Yarrow Bioscience, Logos Global Management, investment adviser, common stock, pre-funded warrants